Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NICE Likely To Lose Cost-Watchdog Status By 2013

This article was originally published in The Pink Sheet Daily

Executive Summary

A new value-based pricing system will make NICE's cost-assessment role redundant, say U.K. ministers.

You may also be interested in...



NICE Will Have Key Role in Value-Based Pricing Under U.K. Health Care Reforms

NICE to be placed on a firmer statutory footing and given a new name, as well as a role in determining the value of medicines.

NICE Will Have Key Role in Value-Based Pricing Under U.K. Health Care Reforms

NICE to be placed on a firmer statutory footing and given a new name, as well as a role in determining the value of medicines.

Avastin's Stumble Again At NICE Underscores Importance Of Overall Survival Data

NICE rejection of Roche's Avastin comes a week ahead of target dates for U.S. and EU decisions on possibly withdrawing the indication, but still offers instructive lessons for working with technology assessment groups.

Related Content

Topics

UsernamePublicRestriction

Register

PS071359

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel